Telix Net Working Capital from 2010 to 2025

TLX Stock   17.98  0.92  4.87%   
Telix Pharmaceuticals Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2025. During the period from 2010 to 2025, Telix Pharmaceuticals Net Working Capital regression line of annual values had r-squared of  0.31 and arithmetic mean of  136,234,788. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
587.7 M
Current Value
617 M
Quarterly Volatility
182.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.4 M, Interest Expense of 38.3 M or Selling General Administrative of 244.5 M, as well as many indicators such as Price To Sales Ratio of 8.16, Days Sales Outstanding of 70.39 or Average Payables of 1.8 M. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Latest Telix Pharmaceuticals' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Telix Pharmaceuticals Limited over the last few years. It is Telix Pharmaceuticals' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Telix Net Working Capital Regression Statistics

Arithmetic Mean136,234,788
Geometric Mean84,772,299
Coefficient Of Variation134.17
Mean Deviation116,527,128
Median73,672,000
Standard Deviation182,781,822
Sample Variance33409.2T
Range607.5M
R-Value0.55
Mean Square Error24842.9T
R-Squared0.31
Significance0.03
Slope21,236,610
Total Sum of Squares501137.9T

Telix Net Working Capital History

2025617 M
2024587.7 M
202367.4 M
202287.7 M
20219.6 M

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital587.7 M617 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.